APOE: A potential marker of disease progression in ALS

被引：60
|
作者：
Lacomblez, L
Doppler, V
Beucler, I
Costes, G
Salachas, F
Raisonnier, A
Le Forestier, N
Pradat, PF
Bruckert, E
Meininger, V
机构：
[1] Hop La Pitie Salpetriere, AH HP, Federat Neurol Mazarin, F-75013 Paris, France
[2] Hop La Pitie Salpetriere, AH HP, Serv Pharmacol, F-75013 Paris, France
[3] Hop La Pitie Salpetriere, AH HP, Serv Endocrinol, F-75013 Paris, France
[4] Hop La Pitie Salpetriere, AH HP, Lab Lipides & Lipoprot, F-75013 Paris, France
来源：
NEUROLOGY | 2002年 / 58卷 / 07期
关键词：
D O I：
10.1212/WNL.58.7.1112
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Although documented in AD, the role of APOE remains unclear in ALS. APOE phenotype and plasma levels were measured in 403 patients with ALS and were cor related with clinical parameters and survival time. No correlations were observed between the APOE phenotype, and these variables. In contrast, APOE plasma levels were correlated with both rate of deterioration and survival time and appeared to be an important risk factor for decreased survival time with a relative risk of 0.647 (95% Cl: 0.465 to 0.901; P = 0.01).
引用
收藏
页码：1112 / 1114
页数：3
相关论文
共 50 条
  • [31] Poly(GP) proteins: a potential pharmacodynamic marker in ALS and FTD
    Budini, Mauricio
    Criollo, Alfredo
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (24)
  • [32] Potential Parkinson disease and ALS drug
    Pamela Feliciano
    Nature Genetics, 2012, 44 (11) : 1178 - 1178
  • [33] Gait phenotype in Batten disease: A marker of disease progression
    Ostergaard, John R.
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2021, 35 : 1 - 7
  • [34] EEG β-power and β-synchrony in the Sensorimotor Network as a Potential Biomarker for Disease Severity and Progression of Motor Symptoms in ALS
    Fasano, Antonio
    Dukic, Stefan
    Coffey, Amina
    Buxo, Teresa
    Mc Mackin, Roisin
    Chipika, Rangariroyashe
    Heverin, Mark
    Bede, Peter
    Muthuraman, Muthuraman
    Lowery, Madeleine
    Carson, Richard
    Nasseroleslami, Bahman
    Hardiman, Orla
    NEUROLOGY, 2020, 94 (15)
  • [35] Exploring Social Determinants of Health in ALS Disease Progression
    Iyer, Amrita
    Burke, Katherine M.
    Clark, Alison P.
    Pant, Pravin
    Scheier, Zoe
    Berry, James D.
    Johnson, Stephen A.
    MUSCLE & NERVE, 2022, 66 : S25 - S25
  • [36] Research on Feature Selection and Predicting ALS Disease Progression
    Li, Jin
    Wang, Shu-Lin
    Wang, JingJing
    INTELLIGENT COMPUTING THEORIES AND APPLICATION, ICIC 2017, PT I, 2017, 10361 : 235 - 246
  • [37] Disease progression in ALS has not changed in the past decade
    Qureshi, Muddasir
    Schoenfeld, David
    Cudkowicz, Merit
    NEUROLOGY, 2008, 70 (11) : A344 - A344
  • [38] Imaging and neurochemical markers for diagnosis and disease progression in ALS
    Karitzky, J
    Ludolph, AC
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2001, 191 (1-2) : 35 - 41
  • [39] ALSFRS predicts survival and measures disease progression in ALS
    Moore, DH
    Miller, RG
    NEUROLOGY, 2004, 62 (07) : A135 - A135
  • [40] Identification of early disease progression in an ALS rat model
    Thonhoff, Jason R.
    Jordan, Paivi A.
    Karam, Joseph R.
    Bassett, Brandon L.
    Wu, Ping
    NEUROSCIENCE LETTERS, 2007, 415 (03) : 264 - 268
12345